Our impact

Cancer impact

Examples of the impact of our researchers onto cancer treatment include:

• contribution to clinical trials that led to a worldwide marketing authorisation of the breast cancer drug lapatinib;
• identification of cost-effective treatment of depression in cancer patients that lead to improved clinical guidelines;
• contributions to improved genetic screening and quantification of genetic risk in colorectal cancer that helped develop new diagnostic tests, improved primary cancer prevention, facilitated genetic counselling and effected clinical guidelines;
• identification of unique clinical phenotype in ovarian cancer (BRCA1/2-deficiency) and development of individualised therapy (also resulting in novel diagnostic-screening recommendations);
• contributions to establishing the role of aspirin as chemopreventive agent in colorectal cancer that resulted in new clinical recommendations;
• contributions to the UK NHS breast cancer screening programme.

Diagnosis of rare genetic disease

Through funding from the Chief Scientist Office, the Centre is participating in an NHS Scotland programme to conduct trio whole exome sequencing for families with a child with a developmental disorder.

More information